Ophthalmologic manifestations in primary antiphospholipid syndrome patients: A cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic review of the literature
Restricted accessResearch articleFirst published online October, 2020
Ophthalmologic manifestations in primary antiphospholipid syndrome patients: A cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic review of the literature
There is a broad spectrum of eye involvement in antiphospholipid syndrome (APS). The majority of descriptions are presented as case reports that include mostly APS patients secondary to systemic lupus erythematosus (SLE), with no compelling evidence in primary APS (PAPS). This study aimed to describe ocular manifestations in our well-defined PAPS cohort (APS-Rio) and then perform a systematic literature review (SLR) of ocular manifestations in patients with APS or positivity to aPL without SLE.
Methods
We retrospectively analyzed PAPS patients followed at our outpatient clinics. All patients fulfilled Sydney APS classification criteria (2006). We evaluated them for ocular symptoms and previous ocular diagnoses. Antiphospholipid antibodies and clinical APS manifestations were compared between patients with and without ocular manifestations. For the SLR, electronic databases were searched up to November 2019.
Results
We studied 105 PAPS patients; 90.5% were female and 56.2% were Caucasian. We found ocular manifestations in 37.1% of our cohort. Thrombosis was the main criteria manifestation (95.2%) and lupus anticoagulant was the most prevalent antibody. Ophthalmologic diagnoses were present in 7 patients, with 5 having retinal vessels thromboses. Amaurosis fugax was the leading complaint, present in 30 patients. In the univariate analysis, amaurosis fugax was related to livedo (p = 0.005), Raynaud’s phenomenon (p = 0.048) and the presence of anticardiolipin antibody (≥40 GPL/MPL) (p = 0.041). Hemianopia was associated with arterial hypertension (p = 0.049). In the multivariate analysis, the only association found was between livedo and amaurosis fugax (OR 4.09, 95%CI 1.5–11.11, p = 0.006). Our SLR incorporated 96 articles of ocular manifestations in patients with PAPS or positivity to aPL without SLE. Ocular findings varied from 5 to 88%, including anterior and posterior segments, orbital and neuro-ophthalmologic changes.
Conclusion
There is little evidence on ocular manifestations in PAPS. We described an association between livedo and amaurosis fugax. Prospective studies are needed to promote the best treatment and avoid blindness in PAPS patients.
MiyakisSLockshinMDAtsumiT, et al.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006;
4: 295–306.
3.
KoikeT.Antiphospholipid syndrome: 30 years and our contribution. Int J Rheum Dis2015;
18: 233–241.
4.
MeroniPLChighizolaCBRovelliFGerosaM.Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther2014;
16: 209.
5.
IslamMAAlamFGanSHSasongkoTH, WGhazaliWSWongKK.A 15-year single centre retrospective study of antiphospholipid syndrome patients from Northern Malaysia. Malays J Pathol2017;
39: 123–133.
YalavarthiSGouldTJRaoAN, et al.
Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol2015;
67: 2990–3003.
9.
ChaturvediSMcCraeKR.Diagnosis and management of the antiphospholipid syndrome. Blood Rev2017;
31: 406–417.
10.
EmmiGSilvestriESquatritoD, et al.
An approach to differential diagnosis of antiphospholipid antibody syndrome and related conditions. Sci World J2014;
2014: 341342.
11.
UtzVMTangJ.Ocular manifestations of the antiphospholipid syndrome. Br J Ophthalmol2011;
95: 454–459.
12.
UtzVMTangJ.Republished review: ocular manifestations of the antiphospholipid syndrome. Postgrad Med J2011;
87: 496–501.
13.
BecarevicMMirkovicDIgnjatovicS.Double positivity of the IgG isotype of both anticardiolipin and anti-beta2gpI antibodies is associated with the highest number of vascular impairment parameters in patients with primary antiphospholipid syndrome: preliminary data. Clin Rheumatol2016;
35: 2947–2954.
14.
BazzanMVaccarinoAStellaS, et al.; for the Piedmont APS Consortium.
Patients with antiphosholipid syndrome and thrombotic recurrences: a real world observation (the piedmont cohort study). Lupus2016;
25: 479–485.
BagheriNMehtaS.Acute vision loss. Prim Care2015;
42: 347–361.
19.
FraserJANewmanNJBiousseV.Disorders of the optic tract, radiation, and occipital lobe. Handb Clin Neurol2011;
102: 205–221.
20.
VashistPSenjamSSGuptaVGuptaNKumarA.Definition of blindness under national programme for control of blindness: do we need to revise it?Indian J Ophthalmol2017;
65: 92–96.
21.
HainerBLMathesonEM.Approach to acute headache in adults. Am Fam Physician2013;
87: 682–687.
22.
TsironiEGatselisNKotoulaMG, et al.
Ocular disorders as the prevailing manifestations of antiphospholipid syndrome: a case series. Cases J2009;
2: 159.
23.
CabritaFVLFosterCS.Anticardiolipin antibodies and ocular disease. Ocul Immunol Inflamm2005;
13: 265–270.
24.
SuvajacGStojanovichLMilenkovichS.Ocular manifestations in antiphospholipid syndrome. Autoimmun Rev2007;
6: 409–414.
25.
MiserocchiEFosterCS.Ocular features associated with anticardiolipin antibodies: a descriptive study. Invest Ophthalmol Vis Sci2000;
41: S783.
26.
CastañónCAmigoMCBañalesJLNavaAReyesPA.Ocular vaso-occlusive disease in primary antiphospholipid syndrome. Ophthalmology1995;
102: 256–262.
27.
DemirciFYKüçükkayaRAkarçayK, et al.
Ocular involvement in primary antiphospholipid syndrome – ocular involvement in primary APS. Int Ophthalmol1998;
22: 323–329.
28.
DurraniOMCameron-SwabyDABowmanSAinsworthJR.Scleritis as the presenting sign of primary antiphospholipid syndrome. Eye (Lond)2001;
15: 558–559.
29.
AllamRAliB.Hypertensive uveitis: an initial presentation for primary antiphospholipid syndrome. Delta J Ophthalmol2017;
18: 185–189.
30.
TakkarBKhokharSKumarUVenkateshP.Necrotising scleritis, keratitis and uveitis in primary antiphospholipid syndrome. BMJ Case Rep2018;
2018: bcr2017220647.
31.
MontehermosoAMejíaJC.Ophthalmological and otological manifestations in the antiphospholipid syndrome. CRR2010;
6: 32–41.
32.
Cobo-SorianoRSánchez-RamónSAparicioMJ, et al.
Antiphospholipid antibodies and retinal thrombosis in patients without risk factors: a prospective case-control study. Am J Ophthalmol1999;
128: 725–732.
33.
AjajALuhishiEMetaraiahE.Primary antiphospholipid syndrome unusual presentation in a seventy two year old man. Libyan J Med2008;
3: 106–107.
34.
WiechensBSchroderJOPotzschBRochelsR.Primary antiphospholipid antibody syndrome and retinal occlusive vasculopathy. Am J Ophthalmol1997;
123: 848–850.
35.
PulidoJSWardLMFishmanGAGoodwinJAFroelichCJSanghviJP.Antiphospholipid antibodies associated with retinal vascular disease. Retina1987;
7: 215–218.
36.
GlacetbernardABayaniNChretienPCochardCLelongFCoscasG.Antiphospholipid antibodies in retinal vascular occlusions – a prospective study of 75 patientes. Arch Ophthalmol1994;
112: 790–795.
37.
SaxonhouseMABhattiMTDriebeWTFreemanBEMariaBLCarneyPR.Primary antiphospholipid syndrome presenting with a branch retinal artery occlusion in a 15-year-old boy. J Child Neurol2002;
17: 392–394.
38.
JabraneMEz-ZahraouiMRHajjiIFadiliWMoutaouakilALaouadI.Central retinal vein occlusion in a patient on hemodialysis secondary to antiphospholipid syndrome: case report. Nephrol Ther2017;
13: 245–247.
39.
QuerquesLTerradaCSouiedEHCorradoACantatoreFPQuerquesG.[Bilateral sequential central retinal vein occlusion associated with primary antiphospholipid syndrome]. J Fr Ophtalmol2012;
35: 443.e1–443.e5.
ZhuWWuYXuM, et al.
Antiphospholipid antibody and risk of retinal vein occlusion: a systematic review and meta-analysis. PLoS One2014;
10: e0122814.
42.
ZhuWWuYXuM, et al.
Correction: antiphospholipid antibody and risk of retinal vein occlusion: a systematic review and meta-analysis. PLoS One2016;
11: e0157536.
BashshurZFTaherAMasriAFNajjarDArayssiTKNoureddinBN.Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors – a prospective study. Retina2003;
23: 486–490.
46.
KeanePARavikumarKO'SheaSIClearyPE.Anti-beta 2 glycoprotein 1 and the anti-phospholipid syndrome. Am J Ophthalmol2006;
142: 701–702.
HartnettMELaposataMVan CottE.Antiphospholipid antibody syndrome in a six-year-old female patient. Am J Ophthalmol2003;
135: 542–544.
49.
MaaroufiRMHamdiRJmiliNGhorbalMHamidaFBHMahjoubT.Antiphospholipid syndrome and retinal vein occlusion in adults. East Mediterr Health J2004;
10: 627–632.
50.
KimJKKimMYYuHSJongHKHwangISLeeCW.Retinal vein occlusion in two patients with primary antiphospholipid syndrome. Korean J Intern Med2001;
16: 274–276.
51.
TavakoliMRoghaeeSSoheilianRSoheilianM.Antiphospholipid syndrome following toxoplasma retinochoroiditis. Ocul Immunol Inflamm2011;
19: 311–313.
52.
ManzanaresJMCongetIRodríguez-VillarC, et al.
Antiphospholipid syndrome in a patient with type I diabetes presenting as retinal artery occlusion. Diabetes Care1996;
19: 92–94.
53.
ZajdenweberMEMuccioliCMoraesRTLoganPFernandesBFBurnierMN.Localized retinal ischemia as an ocular manifestation of primary antiphospholipid syndrome. Can J Ophthalmol2007;
42: 479–480.
54.
DoriDGelfandYABrennerBMillerB.Cilioretinal artery occlusion: an ocular complication of primary antiphospholipid syndrome. Retina1997;
17: 555–557.
55.
GutrechtJAKattwinkelNStillmanMJ.Retinal migraine, chorea, and retinal artery thrombosis in a patient with primary antiphospholipid antibody syndrome. J Neurol1991;
238: 55–56.
56.
CroftsJWNussbaumJJLevineSRFaigJC.Retinitis pigmentosa and branch retinal artery occlusion with anticardiolipin antibody. Arch Ophthalmol1989;
107: 324.
57.
UysalZDoğuFKürekçiAE, et al.
Recurrent arterial thrombosis in a child: primary antiphospholipid antibody syndrome. Pediatr Hematol Oncol2002;
19: 59–66.
58.
McKibbinMParulekarMInnesJR.Recurrent retinal artery occlusion after the disappearance of lupus anticoagulant. Eye (Lond)1998;
12: 893–894.
59.
GiordanoNSenesiMBattistiE, et al.
Antiphospholipid antibodies in patients with retinal vascular occlusions. Acta Ophthalmol Scand1998;
76: 128–129.
60.
CampbellJPBurkholderBMDunnJP.Catastrophic antiphospholipid antibody syndrome and cocaine abuse associated with bilateral retinal vascular occlusions. Retin Cases Brief Rep2011;
5: 318–322.
61.
BeckhauserAPAranaLASkareTL.Antiphospholipid syndrome and bilateral retinal artery and vein occlusion: case report. Arq Bras Oftalmol2008;
71: 282–285.
62.
GelmanRTsangSH.Sequential Central retinal vein and ophthalmic artery occlusions in a pediatric case of primary antiphospholipid syndrome. Retin Cases Brief Rep2016;
10: 58–62.
63.
LevyJBaumgartenARosenthalGRabinowitzRLifshitzT.Consecutive central retinal artery and vein occlusions in primary antiphospholipid syndrome. Retina2002;
22: 784–786.
64.
ConsigliARoquelaureDSouteyrandGChizzoliniCThumannGChronopoulosA.Diagnostic dilemma in sequential branch retinal vein and artery occlusion. Optom Vis Sci2015;
92: e404–e408.
HsiaoYCJouJRLinSYLinSL.Primary antiphospholipid syndrome manifested as venous stasis retinopathy. Zhonghua Yi Xue Za Zhi (Taipei)2000;
63: 498–502.
67.
MariottiCGiovanniniAReibaldiMSaittaAVitiFNicolaiM.Atypical presentation of antiphospholipid syndrome: a case report.Case Rep Ophthalmol2014;
5: 400–404.
68.
MonshizadehRWernerMRichardsHTabandehHBhattiMT.Vitreous hemorrhage as the presenting sign of antiphospholipid syndrome. Can J Ophthalmol2003;
38: 607–609.
69.
KurzDEWangRCKurzPA.Idiopathic retinal vasculitis, aneurysms, and neuroretinitis in a patient with antiphospholipid syndrome. Arch Ophthalmol2012;
130: 257–258.
70.
TurakaKBryanJSKwongHMJrZiemianskiMC.Bilateral occlusive retinal vasculitis in a patient with primary antiphospholipid antibody syndrome. Can J Ophthalmol2012;
47: e60-1–e61.
71.
TranKDReadSPPatelNAFlynnHWJrSchatzNJ.Antiphosphospholipid syndrome presenting with amaurosis fugax and cotton wool spots.Am J Ophthalmol Case Rep2017;
7: 143–145.
72.
AchesonJFGregsonRMCMerryPSchulenburgWE.Vaso-occlusive retinopathy in the primary anti-phospholipid antibody syndrome. Eye (Basingstoke)1991;
5: 48–55.
73.
WoodEHWongRW.Bilateral frosted branch angiitis as the presenting sign of antiphospholipid antibody syndrome. J Ophthalmic Inflamm Infect2016;
6: 20.
74.
AngLPKYapEYFamHB.Bilateral choroidal infarction in a patient with antiphospholipid syndrome: a case report. Clin Experiment Ophthalmol2000;
28: 326–328.
75.
TsironiEGatselisNKotoulaMGChatzoulisDZDalekosGN.Unexplained choroidal embolisation: remember the antiphospholipid syndrome. Lancet2006;
368: 1936.
76.
LylesGWMoyerSChavalaSH.Clinical images: peripheral retinal neovascularization in the antiphospholipid antibody syndrome. Arthritis Rheum2012;
64: 1144.
77.
CuriALLJacksAPavesioC.Choroidal neovascular membrane presenting as a complication of pre-eclampsia in a patient with the antiphospholipid syndrome. Br J Ophthalmol2000;
84: 1075.
78.
CostenMTJOlsonJA.Central serous chorioretinopathy may be a manifestation of the primary antiphospholipid syndrome. Br J Ophthalmol2000;
84: 667.
79.
CostenMTParkinBTDavisonCRCrickMP.Central serous chorioretinopathy and antiphospholipid antibodies – results of a pilot study.Eye (Lond)2004;
18: 938.
80.
RehakMMeierPBuhnerEPetrosSWiedemannP.Occlusion of choroidal vessels in a patient with catastrophic antiphospholipid syndrome. Acta Ophthalmol2011;
89: 595–596.
ArfSMuslubas HocaogluSIKaracorluM.Retinal deep capillary plexus ischemia in a case with antiphospholipid syndrome. Retin Cases Brief Rep2018;
12: 106–110.
85.
SchofieldJRPalestineAGPelakVMathiasMT.Deep capillary retinal ischemia and high-titer prothrombin-associated antiphospholipid antibodies: a case series of three patients.Am J Ophthalmol Case Rep2019;
14: 105–109.
CicinelliMVMarcheseAAragonaEMiserocchiEBandelloFModoratiGM.Ultra-widefield imaging of vasoocclusive retinopathy secondary to antiphospholipid syndrome. Retina2019;
39: e32–e33.
88.
RahimAKumarPBurnsJSampathR.Isolated ocular cutaneous involvement in antiphospholipid syndrome. Orbit2012;
31: 367–369.
89.
NaSKimT.Orbital myositis as a manifestation of primary antiphospholipid syndrome. Neurol Sci2018;
39: 785–787.
90.
DeyMCharles BatesAMcMillanP.Superior ophthalmic vein thrombosis as an initial manifestation of antiphospholipid syndrome. Orbit2013;
32: 42–44.
91.
VaphiadesMSBrockWBrownHHPeturssonGWestfallCT.Catastrophic antiphospholipid antibody syndrome manifesting as an orbital ischemic syndrome. J Neuroophthalmol2001;
21: 260–263.
92.
GelfandYADoriDMillerBBrennerB.Visual disturbances and pathologic ocular findings in primary antiphospholipid syndrome. Ophthalmology1999;
106: 1537–1540.
93.
ValesiniGPrioriRLuanFLFalcoMBalsanoF.Amaurosis fugax and antiphospholipid antibodies.Lancet1990;
336: 374.
94.
RumiVAngeliniLScaioliVD’AngeloABesanaC.Primary antiphospholipid syndrome and neurologic events. Pediatr Neurol1993;
9: 473–475.
ArnsonYShoenfeldYAlonEAmitalH.The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum2010;
40: 97–108.
97.
Serrador-GarcíaMSantos-BuesoESáenz-FrancésFMartínez-de-la-CasaJMGarcía-FeijooJGarcía-SánchezJ.Non-arteritic anterior ischemic optic neuropathy as first manifestation of antiphospholipid syndrome in a young patient. Arch Soc Esp Oftalmol2014;
89: 368–372.
98.
ReinoSMuñoz-RodriguezFJCerveraREspinosaGFontJIngelmoM.Optic neuropathy in the ‘primary’ antiphospholipid syndrome: report of a case and review of the literature. Clin Rheumatol1997;
16: 629–631.
HoDKRamessurRGuptaMMathewsJP.Homonymous hemianopia in the primary antiphospholipid syndrome. BMJ Case Rep2017;
2017: bcr2016218660.
101.
YangHKMoonKWJiMJHanSBHwangJM.Primary antiphospholipid syndrome presenting with homonymous quadrantanopsia. Am J Ophthalmol Case Rep2018;
10: 208–210.
102.
WattsMTGreavesMRennieIGClearkinLG.Antiphospholipid antibodies in the aetiology of ischaemic optic neuropathy. Eye (Lond)1991;
5: 75–79.
103.
Abu el-AsrarAMAl RashaedSAAbdel GaderAG.Anterior ischaemic optic neuropathy associated with central retinal vein occlusion. Eye (Lond)2000;
14: 560–562.
104.
ShinSYLeeJM.A case of multiple cranial nerve palsies as the initial ophthalmic presentation of antiphospholipid syndrome. Korean J Ophthalmol2006;
20: 76–78.
105.
AliNAMTajunisahISubrayanVReddySCGohKJ.Antiphospholipid syndrome manifesting as papilledema. Int J Ophthalmol2008;
1: 277–280.
106.
ChampionBLChoyFSchrieberLRocheJRoweDB.Isolated fascicular oculomotor nerve palsy as the initial presentation of the antiphospholipid syndrome. J Clin Neurosci2002;
9: 691–694.
107.
SmirnovaTVSheludchenkoVMKozlovskayaNLBudzinskayaMVVelievaIA.[Electrophysiological studies of the retina in antiphospholipid syndrome]. Vestn Oftalmol2017;
133: 22–29.
108.
TsakirisDAOsuskyRKaiserHJMueriRFlammerJMarbetGA.Lupus anticoagulants/anticardiolipin antibodies in patients with normal tension glaucoma. Blood Coagul Fibrinolysis1992;
3: 541–545.
109.
ChauhanBCMikelbergFSArtesPH, et al.; Canadian Glaucoma Study Group.
Canadian glaucoma study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change. Arch Ophthalmol2010;
128: 1249–1255.
110.
AltintasOYukselNSonmezGTOzkanBAltintasLCaliskanS.Serum antiphospholipid antibody levels in pseudoexfoliation. J Glaucoma2012;
21: 326–330.
111.
MazeikaiteGKuzmieneLDaveckaiteA, et al.
Serum antiphospholipid antibody level and ocular haemodynamics in eyes with pseudoexfoliation syndrome. Acta Ophthalmol2016;
94: e165–e166.
112.
JanulevicieneISiaudvytyteLDilieneVBarsauskaiteRSieskyBHarrisA.Effect of trabeculectomy on ocular hemodynamic parameters in pseudoexfoliative and primary open-angle glaucoma patients. J Glaucoma2015;
24: e52–e56.
113.
KremmerSKreuzfelderEKleinR, et al.
Antiphosphatidylserine antibodies are elevated in normal tension glaucoma. Clin Exp Immunol2001;
125: 211–215.
114.
KremmerSKreuzfelderEBachorEJahnkeKSelbachJMSeidahmadiS.Coincidence of normal tension glaucoma, progressive sensorineural hearing loss, and elevated antiphosphatidylserine antibodies. Br J Ophthalmol2004;
88: 1259–1262.
115.
ConiglioMPlataniaADi NucciGDArcieriPModzrewskaRMarianiG.Antiphospholipid-protein antibodies are not an uncommon feature in retinal venous occlusions. Thromb Res1996;
83: 183–188.
116.
Leo-KottlerBKleinRBergPAZrennerE.Ocular symptoms in association with antiphospholipid antibodies. Graefes Arch Clin Exp Ophthalmol1998;
236: 658–668.
117.
ToubiEKrauseIFraserA, et al.
Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol2005;
23: 499–504.
118.
FrancèsCBareteSSoriaA.[Dermatologic manifestations of the antiphospholipid syndrome]. Rev Med Interne2012;
33: 200–205.
119.
LallyLSammaritanoLR.Vasculitis in antiphospholipid syndrome. Rheum Dis Clin North Am2015;
41: 109–123.
120.
PaccalinMManicHBoucheG, et al.
Antiphospholipid syndrome in patients with retinal venous occlusion. Thromb Res2006;
117: 365–369.
121.
PuriPSquirrellD.The role of IgM isotype anticardiolipin antibodies in ocular vaso-occlusive disease. Eye (Lond)2001;
15: 365.
122.
DoguluCFKansuTKadayifcilarS.The role of IgM isotype anticardiolipin antibodies in occlusive ocular vascular disease: report of two cases with primary antiphospholipid antibody syndrome. Eye (Lond)2000;
14: 789–790.
123.
PalmowskiAMDenningerEGeiselJPindurGRuprechtKW.Antiphospholipid antibodies in ocular arterial and venous occlusive disease. Invest Ophthalmol Vis Sci2004;
45: 1587.
